TG Therapeutics
TGTX
109 hedge funds and large institutions have $293M invested in TG Therapeutics in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 41 increasing their positions, 17 reducing their positions, and 11 closing their positions.
141% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 17
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
40% more call options, than puts
Call options by funds: $5.56M | Put options by funds: $3.98M
8% more funds holding
Funds holding: 101 → 109 (+8)
1.1% less ownership
Funds ownership: 51.74% → 50.63% (-1.1%)
30% less capital invested
Capital invested by funds: $422M → $293M (-$129M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$28.8M |
| 2 |
SAM
Senzar Asset Management
New York
|
+$4.3M |
| 3 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
+$2.65M |
| 4 |
Goldman Sachs
New York
|
+$2.53M |
| 5 |
JP Morgan Chase
New York
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$14.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$13.1M |
| 3 |
CCI
Columbus Circle Investors
|
-$8.63M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$8.29M |
| 5 |
BM
Bridger Management
New York
|
-$7.89M |
TGTX Hedge Fund Activity: Q4 2017 in Review
109 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2017, worth a combined $293M — down 30% from $422M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new TGTX positions and 11 closed out — a net gain of 8 holders — while 41 added to existing stakes and 17 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $28.8M. The largest seller was Jennison Associates, exiting entirely with an estimated $14.7M sold.
- 109 institutional investors held TG Therapeutics (TGTX) as of Q4 2017, up from 101 in Q3 2017.
- Funds reported $293M of TG Therapeutics stock for Q4 2017, down 30% quarter-over-quarter.
- 19 funds opened new TG Therapeutics positions in Q4 2017 and 11 closed out, a net change of +8 holders.
- The largest TG Therapeutics buyer in Q4 2017 was Avoro Capital Advisors, an estimated $28.8M added.
- The largest TG Therapeutics seller in Q4 2017 was Jennison Associates, an estimated $14.7M sold.
Based on aggregated 13F filings for Q4 2017.